Please use this identifier to cite or link to this item:
|Title:||68Ga-DOTA-Substance-P as a Tool for Diagnostics and Locoregional Administration Follow up of 213Bi-DOTA-Substance-P in the Course of Glioma Therapy|
|Authors:||PAWLAK Dariusz; GARNUSZEK Piotr; MAURIN Michal; KROLICKI Leszek; KUNIKOWSKA Jolanta; MORGENSTERN Alfred; BRUCHERTSEIFER Frank; JAKUCINSKI M; KOZIARA H; KROLICKI B; MIKOLAJCZAK Renata|
|Citation:||World Journal of Nuclear Medicine vol. 12 no. Supplement 1 p. 52-53 (Paper n° O-020)|
|ISSN:||1450-1147 (print), 1607-3312 (online)|
|Type:||Articles in periodicals and books|
|Abstract:||Gliomas, world Health Organization (WHO) grade II-IV, have been shown to consistently overexpress the transmembrane neurokinin type I receptor (NK-1). NK-1 receptors have also been detected in tumor cells inltrating the intra- and peritumoral vasculature. Peptide Substance P is a physiological ligand for NK-1 receptor and can be labeled with various radionuclides using chelators suitable for e.g., 68Ga and 213Bi. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met (O2)11]-substance-P has been reported. In this work, 111In-DOTA-[Thi8, Met (O2)11]-substance-P was used for evaluation of receptor expression and dose distribution (Single-photon emission computed tomography (SPECT) and low-dose computed tomography (CT)). The aim of our work was to perform Positron emission tomography (PET) imaging using 68Ga-DOTA-[Thi8, Met (O2)11]-substance-P co-injected with 213Bi-DOTA-[Thi8, Met (O2)11]-substance-P therapeutic dose administered to the glioma patient via catheter directly to the cavity after tumor resection in order to assess the post-therapeutic dose distribution.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.